search
Back to results

Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis (DONATELLO)

Primary Purpose

Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
GNSC-001
transient immune-modulation
Placebo
Sponsored by
Genascence Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee focused on measuring Gene therapy, Adeno-associated virus, Intra-articular, GNSC-001, Genascence, Knee pain, Knee arthritis, Osteoarthritis

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria: OA in at least one knee (the 'target knee'), confirmed using centrally read X-ray with a Kellgren-Lawrence (KL) score of 2 or 3 Western Ontario & McMaster University Osteoarthritis Index (WOMAC) pain score ≥ 20 (on a 50-point numerical rating scale) in the target knee during the seven days prior to Screening Persistent moderate to severe symptoms in the target knee, despite failure or intolerance of a 3-month trial of at least 2 conservative therapies (e.g., activity modification, weight loss, physical therapy, opioids, and anti-inflammatory medications, and injection of hyaluronic acid or steroids) Presence of synovial fluid on ultrasound and/or high likelihood of successful extraction of synovial fluid Negative pregnancy test at Screening and Baseline (women of childbearing potential [WOCBP]) Key Exclusion Criteria: Current or documented history of inflammatory arthritis (such as gout or rheumatoid arthritis), inflammation of connective tissue, or other immunological disease Any form of joint degeneration as part of another syndrome (e.g., Ehler's Danlos, Stickler syndrome, etc.) Surgery in the target knee within the 6 months prior to screening Previous partial or total joint replacement in target knee Significant and clinically evident malalignment of the target knee that would impact the subject's function, as determined by the Investigator Body mass index (BMI) > 38 kg/m2 Clinically significant abnormal laboratory values at Screening in laboratory parameters that in the opinion of the Investigator, could represent a potential risk to participant safety: Plans to have, elective surgery of other joints or spine or intra-articular injections in the target knee, within the next 12 months

Sites / Locations

  • Altoona Center for Clinical ResearchRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

GNSC-001 (low dose)

GNSC-001 (low dose) + transient immune-modulation

GNSC-001 (high dose)

GNSC-001 (high dose) + transient immune-modulation

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Severity of TEAEs and SAEs

Secondary Outcome Measures

Change in synovial Interleukin-1 Receptor Antagonist (IL-1Ra) levels over time, from Baseline

Full Information

First Posted
April 19, 2023
Last Updated
June 20, 2023
Sponsor
Genascence Corporation
Collaborators
California Institute for Regenerative Medicine (CIRM)
search

1. Study Identification

Unique Protocol Identification Number
NCT05835895
Brief Title
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
Acronym
DONATELLO
Official Title
A Phase 1b, Randomized, Double-Blinded, Placebo-Controlled Dose Ranging Study to Evaluate Safety, Tolerability and Pharmacodynamics of a Single Intra-articular Injection of GNSC-001 Gene Therapy in Subjects With Osteoarthritis of the Knee
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 12, 2023 (Actual)
Primary Completion Date
January 2025 (Anticipated)
Study Completion Date
January 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Genascence Corporation
Collaborators
California Institute for Regenerative Medicine (CIRM)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical study is to determine if a single injection of 1 or more dose levels of adeno-associated virus (AAV) gene therapy (GNSC-001) is safe and tolerated compared to placebo in participants with painful osteoarthritis (OA) of the knee.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis
Keywords
Gene therapy, Adeno-associated virus, Intra-articular, GNSC-001, Genascence, Knee pain, Knee arthritis, Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
GNSC-001 (low dose)
Arm Type
Experimental
Arm Title
GNSC-001 (low dose) + transient immune-modulation
Arm Type
Experimental
Arm Title
GNSC-001 (high dose)
Arm Type
Experimental
Arm Title
GNSC-001 (high dose) + transient immune-modulation
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Genetic
Intervention Name(s)
GNSC-001
Other Intervention Name(s)
sc-rAAV2.5IL-1Ra
Intervention Description
intra-articular injection
Intervention Type
Drug
Intervention Name(s)
transient immune-modulation
Intervention Description
oral
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
intra-articular injection
Primary Outcome Measure Information:
Title
Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time Frame
Month 12
Title
Severity of TEAEs and SAEs
Time Frame
Month 12
Secondary Outcome Measure Information:
Title
Change in synovial Interleukin-1 Receptor Antagonist (IL-1Ra) levels over time, from Baseline
Time Frame
Baseline to Month 1, 3, 6, 12, and 24
Other Pre-specified Outcome Measures:
Title
Immunogenicity of a single dose of GNSC-001
Time Frame
Month 6 and 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: OA in at least one knee (the 'target knee'), confirmed using centrally read X-ray with a Kellgren-Lawrence (KL) score of 2 or 3 Western Ontario & McMaster University Osteoarthritis Index (WOMAC) pain score ≥ 20 (on a 50-point numerical rating scale) in the target knee during the seven days prior to Screening Persistent moderate to severe symptoms in the target knee, despite failure or intolerance of a 3-month trial of at least 2 conservative therapies (e.g., activity modification, weight loss, physical therapy, opioids, and anti-inflammatory medications, and injection of hyaluronic acid or steroids) Presence of synovial fluid on ultrasound and/or high likelihood of successful extraction of synovial fluid Negative pregnancy test at Screening and Baseline (women of childbearing potential [WOCBP]) Key Exclusion Criteria: Current or documented history of inflammatory arthritis (such as gout or rheumatoid arthritis), inflammation of connective tissue, or other immunological disease Any form of joint degeneration as part of another syndrome (e.g., Ehler's Danlos, Stickler syndrome, etc.) Surgery in the target knee within the 6 months prior to screening Previous partial or total joint replacement in target knee Significant and clinically evident malalignment of the target knee that would impact the subject's function, as determined by the Investigator Body mass index (BMI) > 38 kg/m2 Clinically significant abnormal laboratory values at Screening in laboratory parameters that in the opinion of the Investigator, could represent a potential risk to participant safety: Plans to have, elective surgery of other joints or spine or intra-articular injections in the target knee, within the next 12 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anke Fierlinger, MD
Organizational Affiliation
Genascence Corporation
Official's Role
Study Director
Facility Information:
Facility Name
Altoona Center for Clinical Research
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ellen Rosen
Phone
814-693-0300
Ext
188
Email
ellenrosen@altoonaresearch.com
First Name & Middle Initial & Last Name & Degree
Alan Kivitz, MD, CPI

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

We'll reach out to this number within 24 hrs